Big Pharma as a Healthcare Interest Group in America
This paper examines the role of the pharmaceutical industry—commonly called "Big Pharma"—as a powerful interest group in American healthcare, drawing primarily on Boggs's (2006) review essay. It discusses how trade associations such as PhRMA leverage lobbying power in Washington, D.C., to secure favorable regulations, suppress generic drug competition, and limit regulatory oversight. The paper also explores how profit-driven incentives discourage the development of new treatments, encourage overprescription, and contributed to the opioid epidemic. Ultimately, it argues that Big Pharma's outsized political influence keeps the U.S. healthcare system focused on drug interventions rather than health literacy and preventive medicine.
- Introduction: Big Pharma as an Interest Group: Overview of Big Pharma's lobbying role in U.S. healthcare
- Lobbying for Profit Over Patients: PhRMA lobbying suppresses generic drugs and raises costs
- Chronic Disease, Drug Marketing, and Perverse Incentives: Profit motives discourage new treatments for chronic illness
- Overprescription and the Opioid Crisis: Industry influence drives overprescription and addiction crisis
- Big Pharma's Control Over Regulatory Oversight: Pharmaceutical industry shapes FDA regulation and health policy
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper stays tightly focused on a single analytical lens—interest group theory—and applies it consistently to multiple dimensions of pharmaceutical industry influence.
- It builds its argument progressively, moving from lobbying and regulation through prescribing behavior to broader systemic control, giving the essay a clear logical arc.
- Concrete examples (FDA generic-drug equivalency requirements, the opioid epidemic) ground abstract claims about political influence in recognizable real-world outcomes.
Key academic technique demonstrated
The paper demonstrates effective use of a single scholarly source as an analytical framework. Rather than simply summarizing Boggs (2006), the student uses the source to organize and support a series of connected claims, supplementing it with a secondary source (Walters, 2018) at a relevant point. This shows how to build an argument around a core text without over-relying on paraphrase.
Structure breakdown
The paper opens by introducing Big Pharma's role as an interest group and establishing the profit-over-patients thesis. Subsequent paragraphs address lobbying and generic drug suppression, chronic disease profiteering, physician over-prescription, and regulatory capture. Each paragraph develops one facet of the central argument before a synthesizing conclusion calls for preventive medicine as a counterweight to pharmaceutical influence. The structure is linear and cumulative, appropriate for a short analytical essay at the undergraduate level.
Introduction: Big Pharma as an Interest Group
In his review essay, Boggs (2006) examines the role that "Big Pharma"—the pharmaceutical industry—plays as an interest group in American healthcare. Reviewing several books on the subject, Boggs concludes that this interest group is exploiting modern American medicine, law, and capitalist systems to its advantage. He highlights, for instance, how the trade association PhRMA is one of the largest interest groups in Washington, D.C., and how it uses its influence and financial resources to lobby for regulations that benefit rather than harm Big Pharma. It is a relationship that reflects poorly on both the drug industry and the healthcare industry, as Boggs (2006) exposes a quid pro quo dynamic in which profits are consistently placed before patients.
Lobbying for Profit Over Patients
Boggs (2006) explains that in the United States, the healthcare industry operates as a for-profit business. One way that profits are placed before patients is through lobbying by special interest groups, such as Big Pharma—the collective of drug companies that band together in organizations like PhRMA. Big Pharma as a whole lobbies for regulations that benefit drug companies rather than patients. For example, the FDA requires a generic version of a drug to be proven equivalent to the brand-name version before it can be sold. However, this process is lengthy and expensive, meaning most generic alternatives never reach the market. As a result, patients are forced to pay high prices for brand-name drugs even when cheaper alternatives exist.
Chronic Disease, Drug Marketing, and Perverse Incentives
Big Pharma also manufactures many of the drugs used to treat chronic conditions such as heart disease and diabetes. These drugs are essential for patients, but they are also highly profitable for drug companies. As a result, drug companies have little incentive to develop new treatments or cures for these conditions. Instead, they focus on marketing existing drugs and finding new applications for them. This profit-driven approach to healthcare often means that patients are treated as consumers rather than as sick people in need of genuine medical care (Boggs, 2006; Walters, 2018).
References
Boggs, C. (2006). Review essay: Big Pharma and American medicine. New Political Science, 27(3), 407–421.
Walters, J. (2018). Interview: 'I don't know how they live with themselves' – artist Nan Goldin takes on the billionaire family behind OxyContin. Retrieved from https://www.theguardian.com/artanddesign/2018/jan/22/nan-goldin-interview-us-opioid-epidemic-heroin-addict-oxycontin-sackler-family
Always verify citation format against your institution’s current style guide requirements.